The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.
 
David Camidge
Honoraria - Abbvie; Apollomics; AstraZeneca; Daiichi Sankyo; Janssen; Kestrel Labs; Lilly; Nuvalent, Inc.; Roche; takeda
Research Funding - Inivata (Inst)
 
Judith Raimbourg
Honoraria - Amgen; BMS GmbH & Co. KG; Janssen; Merck; MSD Oncology; Sanofi Pasteur; Servier
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Janssen Oncology; MSD; Pierre Fabre
 
Yun-Gyoo Lee
No Relationships to Disclose
 
Maria J. de Miguel
Honoraria - HiFiBiO Therapeutics; MSD Oncology; PharmaMar
Travel, Accommodations, Expenses - Lilly
(OPTIONAL) Uncompensated Relationships - Abbvie; Abbvie; Array BioPharma; Genmab; HiFiBiO Therapeutics; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Salubris Biotherapeutics; Sanofi; Seagen; SERVIER
 
Antoine Hollebecque
Honoraria - Amgen; BMS; Eisai; Incyte; MSD Oncology; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Pierre Fabre; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Chong Kun Dang Pharmaceutical; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Merck KGaA; Novartis; Regeneron; Roche; Samsung Bioepis; Takeda
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Enliven Therapeutics (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Yuhan (Inst)
 
Yutaka Fujiwara
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Johnson and Johnson; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chiome Bioscience; Daiichi Sankyo; Nippon Kayaku; Ono Pharmaceutical; Otsuka
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Incyte (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novocure (Inst); Shanghai Junshi BioSciences (Inst); Taiho Pharmaceutical (Inst)
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; ChongKeunDang Healthcare; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; ST Cube; Takeda; Yuhan
Consulting or Advisory Role - ABION; ST Cube
 
Jonathan Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genentech; Summit Biomedical
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Pfizer (Inst); Summit Biomedical (Inst)
 
Mor Moskovitz
Honoraria - Abbvie; AstraZeneca; BMSi; Johnson & Johnson/Janssen; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; JNJ; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - MSD; Pfizer; Roche
 
Takako Nakajima
Honoraria - Bristol-Myers Squibb Japan; Celltrion Healthcare Japan K.K.; Chugai Pharma; Daiichi Sankyo/UCB Japan; IQVIA SolutionsJapan K.K.; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - FIMECS, Inc.; Shinobi Therapeutics; Thyas Co. Ltd (Inst)
Research Funding - Abbvie (Inst); BTB Therapeutics; Chugai Pharma (Inst); Immunohelix; IQVIA Solutions Japan K.K.; KBBM (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical; Parexel international inc; Taiho Pharmaceutical (Inst); Taisho Pharmaceutical Holdings (Inst); Takeda (Inst); Thermo Fisher Scientific; Zymeworks (Inst)
 
David Baz
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead/Forty Seven; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca
 
Zoe Hunter
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Michael Burns
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
 
Martha Blaney
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Rui Li
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Tony Navas
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Theodore Jennaro
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
David Sommerhalder
Employment - Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology/US Oncology
Honoraria - Syneos Health
Consulting or Advisory Role - Nimbus Therapeutics; Revolution Medicines
Research Funding - Abbvie (Inst); Acrivon Therapeutics (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Day One Biopharmaceuticals (Inst); Dicerna (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Pharmaceutical (Inst); IconOVir Bio (Inst); Immuneering (Inst); IMPAC Medical Systems (Inst); Incendia Pharmaceuticals AB (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Novo Nordisk (Inst); OBI Pharma (Inst); OncoResponse (Inst); Pfizer (Inst); Revolution Medicines (Inst); Step Pharma (Inst); Symphogen (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Tyligand Bioscience (Inst); Vincera Pharma/Vincerx Pharma (Inst); Vividion Therapeutics (Inst); ZielBio (Inst); Zymeworks (Inst)